• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday

    6/20/24 8:11:28 AM ET
    $BFH
    $C
    $CROX
    $ESPR
    Real Estate
    Real Estate
    Major Banks
    Finance
    Get the next $BFH alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

    • Evercore ISI Group raised the price target for Bread Financial Holdings, Inc. (NYSE:BFH) from $42 to $45. Evercore ISI Group analyst John Pancari upgraded the stock from Underperform to In-Line. Bread Financial shares gained 0.5% to close at $40.84 on Tuesday. See how other analysts view this stock.
    • TD Cowen raised the price target for Ocular Therapeutix, Inc. (NASDAQ:OCUL) from $7 to $11. TD Cowen analyst Tara Bancroft upgraded the stock from Hold to Buy. Ocular Therapeutix shares fell 0.2% to close at $5.49 on Tuesday. See how other analysts view this stock.
    • Evercore ISI Group increased KB Home (NYSE:KBH) price target from $78 to $86. Evercore ISI Group analyst Stephen Kim maintained an Outperform rating. KB Home shares fell 2.1% to close at $68.04 on Tuesday. See how other analysts view this stock.
    • HC Wainwright & Co. cut the price target for Shattuck Labs, Inc. (NASDAQ:STTK) from $28 to $16. HC Wainwright & Co. analyst Joseph Pantginis maintained a Buy rating. Shattuck Labs shares fell 7.8% to close at $4.59 on Tuesday. See how other analysts view this stock.
    • B of A Securities slashed Esperion Therapeutics, Inc. (NASDAQ:ESPR) price target from $2.9 to $2.5. B of A Securities analyst Jason Zemansky downgraded the stock from Neutral to Underperform. Esperion Therapeutics shares fell 5.2% to close at $2.72 on Tuesday. See how other analysts view this stock.
    • Baird boosted Workday, Inc. (NASDAQ:WDAY) price target from $277 to $316. Baird analyst Mark Marcon maintained an Outperform rating. Workday shares fell 2.2% to close at $207.69 on Tuesday. See how other analysts view this stock.
    • Bernstein boosted the price target for Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) from $150 to $200. Bernstein analyst Mark Li maintained an Outperform rating. Taiwan Semiconductor Manufacturing shares gained 1.4% to close at $179.69 on Tuesday. See how other analysts view this stock.
    • Keybanc increased Meta Platforms, Inc. (NASDAQ:META) price target from $475 to $540. Keybanc analyst Justin Patterson maintained an Overweight rating. Meta Platforms shares fell 1.4% to close at $499.49 on Tuesday. See how other analysts view this stock.
    • Keefe, Bruyette & Woods raised Citigroup Inc. (NYSE:C) price target from $66 to $69. Keefe, Bruyette & Woods analyst David Konrad maintained a Market Perform rating. Citigroup shares gained 1.2% to close at $60.78 on Tuesday. See how other analysts view this stock.
    • B of A Securities boosted Crocs, Inc. (NASDAQ:CROX) price target from $160 to $187. B of A Securities analyst Christopher Nardone maintained a Buy rating. Crocs shares fell 0.2% to close at $159.42 on Tuesday. See how other analysts view this stock.

    Check This Out: Hewlett Packard Enterprise, Accenture And 3 Stocks To Watch Heading Into Thursday

    Get the next $BFH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFH
    $C
    $CROX
    $ESPR

    CompanyDatePrice TargetRatingAnalyst
    Bread Financial Holdings Inc.
    $BFH
    2/5/2026$90.00In-line → Outperform
    Evercore ISI
    Meta Platforms Inc.
    $META
    1/29/2026$770.00 → $800.00Overweight
    Barclays
    Meta Platforms Inc.
    $META
    1/29/2026$830.00 → $872.00Buy
    UBS
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $850.00Outperform
    Wolfe Research
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $850.00Buy
    Roth Capital
    Meta Platforms Inc.
    $META
    1/29/2026$800.00 → $825.00Overweight
    Analyst
    Meta Platforms Inc.
    $META
    1/29/2026$754.00 → $849.00Overweight
    Wells Fargo
    Meta Platforms Inc.
    $META
    1/29/2026$840.00 → $880.00Overweight
    Piper Sandler
    More analyst ratings

    $BFH
    $C
    $CROX
    $ESPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Replogle John B bought $223,500 worth of shares (3,000 units at $74.50), increasing direct ownership by 19% to 18,417 units (SEC Form 4)

    4 - Crocs, Inc. (0001334036) (Issuer)

    11/12/25 5:05:25 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:50:52 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFH
    $C
    $CROX
    $ESPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Olivan Javier sold $342,869 worth of shares (517 units at $663.19), decreasing direct ownership by 5% to 9,098 units (SEC Form 4)

    4 - Meta Platforms, Inc. (0001326801) (Issuer)

    2/11/26 6:17:22 PM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    CEO Eschenbach Carl M. covered exercise/tax liability with 1,674 shares, decreasing direct ownership by 0.27% to 622,969 units (SEC Form 4)

    4 - Workday, Inc. (0001327811) (Issuer)

    2/9/26 4:30:51 PM ET
    $WDAY
    EDP Services
    Technology

    Chief Operating Officer Notman Donald sold $101,398 worth of shares (11,490 units at $8.82), decreasing direct ownership by 3% to 377,802 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/4/26 8:23:42 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFH
    $C
    $CROX
    $ESPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFH
    $C
    $CROX
    $ESPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bread Financial upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Bread Financial from In-line to Outperform and set a new price target of $90.00

    2/5/26 6:50:02 AM ET
    $BFH
    Real Estate

    Barclays reiterated coverage on Meta Platforms with a new price target

    Barclays reiterated coverage of Meta Platforms with a rating of Overweight and set a new price target of $800.00 from $770.00 previously

    1/29/26 9:46:59 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    UBS reiterated coverage on Meta Platforms with a new price target

    UBS reiterated coverage of Meta Platforms with a rating of Buy and set a new price target of $872.00 from $830.00 previously

    1/29/26 9:46:59 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    $BFH
    $C
    $CROX
    $ESPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    Crocs, Inc. Reports Fourth Quarter and Full-Year 2025 Results; Issues First Quarter and Full-Year 2026 Outlook

    Full-Year 2025 Results Outperform Expectations on Revenue and Earnings Per ShareStrong Cash Flow Enabled Repurchase of 6.5 Million Shares for $577 Million in 2025Expects to Deliver Earnings Per Share Growth in Full-Year 2026BROOMFIELD, Colo., Feb. 12, 2026 /PRNewswire/ -- Crocs, Inc. (NASDAQ:CROX), a world leader in innovative casual footwear for all, today announced its fourth quarter and full-year 2025 financial results. "We ended 2025 on a strong note with a better-than-expected Holiday quarter. For the year, revenue exceeded $4 billion, led by low-double digit international growth for the Crocs Brand. At the same time, we accelerated our strategic actions to strengthen the long-term heal

    2/12/26 7:00:00 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shar

    2/11/26 4:30:00 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFH
    $C
    $CROX
    $ESPR
    SEC Filings

    View All

    SEC Form 10-K filed by Crocs Inc.

    10-K - Crocs, Inc. (0001334036) (Filer)

    2/12/26 3:03:37 PM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    SEC Form FWP filed by Citigroup Inc.

    FWP - CITIGROUP INC (0000831001) (Subject)

    2/12/26 1:01:57 PM ET
    $C
    Major Banks
    Finance

    Crocs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Crocs, Inc. (0001334036) (Filer)

    2/12/26 7:01:52 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    $BFH
    $C
    $CROX
    $ESPR
    Leadership Updates

    Live Leadership Updates

    View All

    Sunbit Appoints Shachar G. Scott as Chief Marketing Officer to Accelerate its Next Phase of Growth

    Veteran global marketing leader joins from Meta as Sunbit scales products, partnerships and infrastructure to serve millions more consumers Sunbit, the personalized financial partner for everyday life, today announced the appointment of Shachar G. Scott as Chief Marketing Officer, signaling a pivotal next chapter in the company's growth. Scott brings more than 25 years of experience building and scaling global brands across technology and consumer products with leadership roles at Meta (NASDAQ:META), Apple (NASDAQ:AAPL), Bumble (NASDAQ:BMBL) and Snap (NYSE:SNAP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260212757677/en/S

    2/12/26 10:14:00 AM ET
    $AAPL
    $BMBL
    $META
    Computer Manufacturing
    Technology
    Computer Software: Programming Data Processing

    Workday Announces CEO Transition as Co-Founder Aneel Bhusri Returns to Lead the Company's Next Chapter

    Carl Eschenbach Steps Down After Leading Company Through a Period of Global Expansion and Operational Scale Company Reaffirms Fiscal 2026 Fourth Quarter and Full-Year Outlook PLEASANTON, Calif., Feb. 9, 2026 /PRNewswire/ -- Workday, Inc. (NASDAQ:WDAY), the enterprise AI platform for managing people, money, and agents, today announced that co-founder and current executive chair Aneel Bhusri is returning as chief executive officer as the company enters its next chapter, focused on leading in the rapidly evolving AI era. Carl Eschenbach is stepping down as CEO and as a member of the board after leading Workday through a period defined by global growth, an expanded industry focus, and strengthen

    2/9/26 8:30:00 AM ET
    $WDAY
    EDP Services
    Technology

    KB HOME NAMES ROBERT MCGIBNEY CHIEF EXECUTIVE OFFICER

    Jeffrey Mezger Becomes Company's First Executive Chairman LOS ANGELES, Jan. 28, 2026 /PRNewswire/ -- KB Home (NYSE:KBH) today announced that, as part of its long-term succession planning process, its board of directors appointed Robert McGibney as President and Chief Executive Officer, effective March 1, 2026.  At that time, McGibney, a KB Home veteran with over 25 years of service, will succeed Jeffrey Mezger, who will become KB Home's first Executive Chairman of the board after serving as Chief Executive Officer for two decades and Chairman since 2016.  The board also appoi

    1/28/26 4:10:00 PM ET
    $KBH
    Homebuilding
    Consumer Discretionary

    $BFH
    $C
    $CROX
    $ESPR
    Financials

    Live finance-specific insights

    View All

    Crocs, Inc. Reports Fourth Quarter and Full-Year 2025 Results; Issues First Quarter and Full-Year 2026 Outlook

    Full-Year 2025 Results Outperform Expectations on Revenue and Earnings Per ShareStrong Cash Flow Enabled Repurchase of 6.5 Million Shares for $577 Million in 2025Expects to Deliver Earnings Per Share Growth in Full-Year 2026BROOMFIELD, Colo., Feb. 12, 2026 /PRNewswire/ -- Crocs, Inc. (NASDAQ:CROX), a world leader in innovative casual footwear for all, today announced its fourth quarter and full-year 2025 financial results. "We ended 2025 on a strong note with a better-than-expected Holiday quarter. For the year, revenue exceeded $4 billion, led by low-double digit international growth for the Crocs Brand. At the same time, we accelerated our strategic actions to strengthen the long-term heal

    2/12/26 7:00:00 AM ET
    $CROX
    Shoe Manufacturing
    Consumer Discretionary

    Bread Financial Provides Performance Update for January 2026

    COLUMBUS, Ohio, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bread Financial® Holdings, Inc. (NYSE:BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company's Net principal loss rate and Delinquency rate for the periods indicated:  For themonth endedJanuary 31, 2026 For themonth endedJanuary 31, 2025 (dollars in millions)End-of-period credit card and other loans$18,386  $18,366 Average credit card and other loans$18,531  $18,530 Year-over-year change in average credit card and other loans —%  (2%)Net principal losses$111  $123 Net princ

    2/10/26 7:00:00 AM ET
    $BFH
    Real Estate

    Citigroup Announces Full Redemption of Series X Preferred Stock

    Citigroup Inc. is redeeming, in whole, all $2.3 billion aggregate liquidation preference of Series X Depositary Shares representing interests in its 3.875% Fixed Rate Reset Noncumulative Preferred Stock, Series X (the "Preferred Stock"). The redemption date is February 18, 2026, for the Preferred Stock and related Depositary Shares (the "Redemption Date"). The cash redemption price, payable on the Redemption Date for each Depositary Share, will equal $1,000. Holders of record on February 6, 2026, will receive the previously declared regular quarterly dividend of $9.6875 per Depositary Share payable on the Redemption Date. The redemption announced today reflects Citigroup's ongoing effor

    2/5/26 8:16:00 AM ET
    $C
    Major Banks
    Finance

    $BFH
    $C
    $CROX
    $ESPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Citigroup Inc.

    SC 13D - CITIGROUP INC (0000831001) ()

    1/5/94 12:00:00 AM ET
    $C
    Major Banks
    Finance

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care